ACSL3 and Ferroptosis Resistance in Cholangiocarcinoma
Author Information
Author(s): Sae-Fung Apiwit, Vinayavekhin Nawaporn, Fadeel Bengt, Jitkaew Siriporn
Primary Institution: Chulalongkorn University, Bangkok, Thailand
Hypothesis
ACSL3 is a potential ferroptosis suppressor in cholangiocarcinoma (CCA) patients.
Conclusion
ACSL3 is identified as an unfavorable prognostic marker in CCA, correlating with increased resistance to ferroptosis.
Supporting Evidence
- ACSL3 was significantly upregulated in high-risk CCA patients compared to low-risk patients.
- High ACSL3 expression correlated with shorter survival in CCA patients.
- Silencing ACSL3 sensitized CCA cells to ferroptosis inducers.
Takeaway
This study found that a protein called ACSL3 helps cancer cells resist a type of cell death called ferroptosis, which is important for treating bile duct cancer.
Methodology
The study analyzed mRNA expression in CCA patients and cell lines, performed lipidomic analysis, and silenced ACSL3 to assess its role in ferroptosis resistance.
Participant Demographics
Patients with cholangiocarcinoma, specifically stratified into low-risk and high-risk groups based on ferroptosis-related gene expression.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website